<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- March 12 2025 ASKA Pharmaceutical Co., Ltd. R&D Presentation for Investors[PDF](held on March 12,2025)
- March 10 2025 ASKA Pharmaceutical Holdings Group Recognized as White 500 Enterprise for Seventh Consecutive Year
- March 10 2025 ASKA Initiates Phase I II Clinical Trial of Drospirenone Agent (LPRI-CF113) in Japan
- February 21 2025 Organizational and Personnel Changes of ASKA Pharmaceutical
- February 3 2025 Notice Concerning Consolidation of Ha Tay Pharmaceutical Joint Stock Company as Consolidated Subsidiary
- January 28 2025 ASKA and SUSMED Start Specified Clinical Trial Using Digital Therapeutics App Designed for Patients with PMS/PMDD
- January 14 2025 Veneno Technologies and ASKA Signed a Joint Research Agreement for the Development of Novel Ion Channel Therapeutics
- December 27 2024 Additional Indication of Sclerotherapy of Venous Malformations for OLDAMIN for Injection 1g in Japan
- December 25 2024 ASKA Pharmaceutical and Insud Pharma Have Entered into a New License Agreement
- December 16 2024 ASKA Initiates Domestic Phase III Clinical Trial of Relugolix Combination Tablet
- November 25 2024 ASKA Pharmaceutical Terminates Joint Development and Option Agreement for a PMS/PMDD Agent with Renascience
- November 13 2024 ASKA Pharmaceutical Presents the Results of Phase III Clinical Trial for Oral Contraceptive LF111 at a Conference
- September 24 2024 TechDoctor and ASKA Pharmaceutical Launch Joint Research on Dysmenorrhea in Cooperation with Healthcare App "4MOON"
- August 23 2024 Personnel Change of ASKA Pharmaceutical
- August 16 2024 ASKA Pharmaceutical licensee Hyundai Receives Manufacturing and Marketing Approval in Republic of Korea for Oral Contraceptive Drospirenone
- June 25 2024 Personnel Changes of Board Members and Corporate Officers of ASKA Pharmaceutical Holdings Subsidiaries
- June 24 2024 ASKA Pharmaceutical Files an Application for Manufacturing and Marketing Approval for LF111 in Japan
- May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area
- April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries
- April 11 2024 ASKA Pharmaceutical Achieves the Primary Endpoint of Phase III Clinical Trial on LF111 in Japan
- April 1 2024 ASKA Pharmaceutical Initiates “Work Support Grant” Program and Cancer Insurance Program for All Regular Employees
- April 1 2024 Organizational and Personnel Changes of ASKA Pharmaceutical
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.